Following promising phase III trial results and accompanying its clinical implementation, the cost-effectiveness of MIDO for the treatment of FLT3 mutation-positive AML was methodically analysed, as dictated by the standards of the field. The gene discussed is FLT3; the disease is acute myeloid leukemia.